Press Releases
Press Releases
Botanix receives export and import approvals for clinical studies from DEA
Botanix Pharmaceuticals is pleased to announce that the US Drug Enforcement Agency (DEA) has approved the export, and the Australian Office of Controlled Substances (ODC) has approved the import of synthetic cannabidiol for Botanix’s planned clinical studies. ...
Press Releases
Citius Pharma Announces Addition of South America to World License
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™. ...
Press Releases
Aptar Pharma Preservative-Free Multidose Dispenser Chosen For The First Time For A Prescription Dry Eye Product In The Us With Restasis Multidose
Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the U.S. prescription market for the first time with Allergan’s RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%. Aptar Pharma is working closely with...
Press Releases
Recipharm partners with Sato to manufacture product for Japanese market
Recipharm, the contract development and manufacturing organisation (CDMO), has entered into a long term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of Emla Patch to Japan. Sato, based in Tokyo and founded...
Press Releases
X-Chem Announces Strategic Collaboration with Astellas Pharma Across Multiple Therapeutic Areas
X-Chem, Inc. , a privately held biotechnology company applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, announced the signing of a broad drug discovery collaboration with Astellas Pharma Inc. The...
Press Releases
Lilly’s Taltz Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis
Eli Lilly and Company announced today that the U.S. FDA has approved Taltz® injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Taltz should...
Press Releases
Acura Pharmaceuticals and MainPointe Pharmaceuticals Announce Deal for Nexafed Products
Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED and NEXAFED Sinus in the US and Canada. The pseudoephedrine-containing NEXAFED brand...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read